Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Parkinson’s Disease Treatment Incidence and Prevalence (2023)
5.2 Parkinson’s Disease Treatment Hospital Trends, (2023), by Region
5.3 Parkinson’s Disease Treatment Drug Volume: Production and usage volumes of pharmaceuticals.
5.4 Hospitalcare Spending, by region, (Government, Commercial, Private, Out-of-Pocket), 2023
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Parkinson’s Disease Treatment Market Segmentation, by Drug Class
7.1 Chapter Overview
7.2 Carbidopa-Levodopa
7.2.1 Carbidopa-Levodopa Market Trends Analysis (2020-2032)
7.2.2 Carbidopa-Levodopa Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Dopamine Agonists
7.3.1 Dopamine Agonists Market Trends Analysis (2020-2032)
7.3.2 Dopamine Agonists Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 MAO-B Inhibitors
7.4.1 MAO-B Inhibitors Market Trends Analysis (2020-2032)
7.4.2 MAO-B Inhibitors Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 COMT Inhibitors
7.5.1 COMT Inhibitors Market Trends Analysis (2020-2032)
7.5.2 COMT Inhibitors Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Anticholinergics
7.6.1 Anticholinergics Market Trends Analysis (2020-2032)
7.6.2 Anticholinergics Market Size Estimates and Forecasts to 2032 (USD Billion)
7.7 Others
7.7.1 Others Market Trends Analysis (2020-2032)
7.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Parkinson’s Disease Treatment Market Segmentation, by Sales Channel
8.1 Chapter Overview
8.2 Hospital
8.2.1 Hospital Market Trends Analysis (2020-2032)
8.2.2 Hospital Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Retail
8.3.1 Retail Market Trends Analysis (2020-2032)
8.3.2 Retail Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Online
8.4.1 Online Market Trends Analysis (2020-2032)
8.4.2 Online Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Parkinson’s Disease Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.2.4 North America Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.2.5.2 USA Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.2.6.2 Canada Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.2.7.2 Mexico Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Parkinson’s Disease Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.1.5.2 Poland Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.1.6.2 Romania Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.1.7.2 Hungary Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.1.8.2 Turkey Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Parkinson’s Disease Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.4 Western Europe Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.5.2 Germany Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.6.2 France Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.7.2 UK Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.8.2 Italy Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.9.2 Spain Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.12.2 Austria Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.4 Asia-Pacific
9.4.1 Trends Analysis
9.4.2 Asia-Pacific Parkinson’s Disease Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia-Pacific Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.4.4 Asia-Pacific Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.4.5.2 China Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.4.5.2 India Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.4.5.2 Japan Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.4.6.2 South Korea Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.2.7.2 Vietnam Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.4.8.2 Singapore Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.4.9.2 Australia Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.4.10 Rest of Asia-Pacific
9.4.10.1 Rest of Asia-Pacific Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia-Pacific Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Parkinson’s Disease Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.1.4 Middle East Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.1.5.2 UAE Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.1.6.2 Egypt Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.1.8.2 Qatar Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Parkinson’s Disease Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.2.4 Africa Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.2.5.2 South Africa Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.5.2.7 Rest of Africa
9.5.2.7.1 Rest of Africa Parkinson’s Disease Treatment Market Estimates and Forecasts, by Component (2020-2032) (USD Billion)
9.5.2.7.2 Rest of Africa Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Parkinson’s Disease Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.6.4 Latin America Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.6.5.2 Brazil Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.6.6.2 Argentina Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.6.7.2 Colombia Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Parkinson’s Disease Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America Parkinson’s Disease Treatment Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10. Company Profiles
10.1 AbbVie
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
110.1.4 SWOT Analysis
10.2 Johnson & Johnson
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 Novartis
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 Teva Pharmaceutical Industries
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 UCB Pharma
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 Prevail Therapeutics (acquired by Eli Lilly)
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 Voyager Therapeutics
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Inflazome
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 Denali Therapeutics
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
